Hemophilia is an inherited bleeding disorder caused by deficiency of clotting factors, leading to impaired blood clot formation and prolonged bleeding. Hemophilia A and B are the most common forms, related to factor VIII and factor IX deficiency respectively. Severity depends on residual factor activity and can include spontaneous or trauma-related bleeding into joints and vital organs.
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
Pfizer reported new clinical and regulatory milestones across oncology, obesity and hemophilia, including BREAKWATER Phase 3 data and Priority Review for HYMPAVZI. The company also cited MagnetisMM-5 results and FDA priority review for PADCEV.
Multiple research teams have developed innovative diabetes treatments including implantable insulin-producing cell devices, an oral insulin delivery platform using peptides, and a biological implant that functions as an autonomous artificial pancreas. These approaches have shown promising results in animal studies, with some devices maintaining glucose control for 90 days or more without immune suppression. The technologies represent potential alternatives to daily insulin injections for millions of diabetes patients worldwide.
International Rare Disease Day on February 28 underscores challenges in diagnosing and treating rare genetic conditions, with patients facing years-long diagnostic delays and geographic barriers to accessing gene therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07579585 |
Effects of Photobiomodulation in Hemophilia Patients. |
RECRUITING | NA |
| NCT07516730 |
Central Pain Mechanisms and Clinical and Psychological Factors Associated With Pain Interference in Daily Life in Adults With Hemophilia and Hemophilic Arthropathy |
NOT_YET_RECRUITING | |
| NCT07454239 |
EPOCH-Economics and Patient Outcomes in China in Haemophilia |
ACTIVE_NOT_RECRUITING | |
| NCT07452575 |
3D Ultrasound in Hemophilic Ankles |
NOT_YET_RECRUITING | NA |
| NCT07425327 |
Validity and Reliability of the Two-minute Step Test in Hemophilia |
NOT_YET_RECRUITING | |
| NCT07420387 |
Effectiveness of an Educational Program for Pain Management in Patients With Hemophilic Arthropathy |
NOT_YET_RECRUITING | NA |
| NCT07420348 |
Incidence of Ultrasonographically Detected Articular Damage in Initially Healthy Joints of Patients With Hemophilia A Receiving Prophylactic Treatment With Emicizumab |
NOT_YET_RECRUITING | |
| NCT07406139 |
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） |
RECRUITING | PHASE4 |
| NCT07339410 |
Physiotherapy to Improve Balance and Walking Capacity in Hemophilia |
COMPLETED | NA |
| NCT07285460 |
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B |
RECRUITING | PHASE3 |
